Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises. N. Engl. J. Med. 251(10), 396–400 (1954).
  Medline CASGoogle Scholar
• 2 Fajgenbaum DC, Van Rhee F, Nabel CS. HhHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123(19), 2924–2933 (2014). •• Of considerable interest, because this paper synthesized the published literature and presented a new classification system as well as model of pathogenesis.
  Medline CASGoogle Scholar
• 3 Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74(4), 1360–1367 (1989).
  Medline CASGoogle Scholar
• 4 Munshi N, Mehra M, Van De Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk. Lymphoma 56(5), 1252–1260 (2015).
  MedlineGoogle Scholar
• 5 Robinson D, Reynolds M, Casper C et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two us treatment centres. Br. J. Haematol. 165(1), 39–48 (2014).
  Medline CASGoogle Scholar
• 6 Bowne WB, Lewis JJ, Filippa DA et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 85(3), 706–717 (1999).
  Medline CASGoogle Scholar
• 7 Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 43(8), 698–704 (2004).
  MedlineGoogle Scholar
• 8 Dispenzieri A, Armitage JO, Loe MJ et al. The clinical spectrum of Castleman's disease. Am. J. Hematol. 87(11), 997–1002 (2012). • Of interest, because this study provided clinical information and survival data on a large series of MCD cases.
  MedlineGoogle Scholar
• 9 Fajgenbaum D, Liu A, Ruth J et al. Hhv-8-negative, idiopathic multicentric Castleman disease (IMCD): a description of clinical features and therapeutic options through a systematic literature review. Blood (ASH Annual Meeting Abstracts), 124 (2014).
  MedlineGoogle Scholar
• 10 Fajgenbaum D, Rosenbach M, Van Rhee F, Nasir A, Reutter J. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA Dermatol. 149(2), 204–208 (2013).
  MedlineGoogle Scholar
• 11 Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv. Anat. Pathol. 16(4), 236–246 (2009).
  MedlineGoogle Scholar
• 12 El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 16(4), 497–511 (2011).
  Medline CASGoogle Scholar
• 13 Dossier A, Meignin V, Fieschi C, Boutboul D, Oksenhendler E, Galicier L. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin. Infect. Dis. 56(6), 833–842 (2013). • Of interest, because this study demonstrated that HHV-8-positive MCD cases, regardless of HIV status, are very similar.
  Medline CASGoogle Scholar
• 14 Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103(5), 1632–1634 (2004).
  Medline CASGoogle Scholar
• 15 Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr. Opin. Oncol. 24(5), 495–505 (2012). • Of interest, because this paper provides a systematic review of KSHV or HHV-8-associated MCD.
  Medline CASGoogle Scholar
• 16 Gerard L, Berezne A, Galicier L et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: Anrs 117 castlemab trial. J. Clin. Oncol. 25(22), 3350–3356 (2007).
  Medline CASGoogle Scholar
• 17 Van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin. Adv. Hematol. Oncol. 8(7), 486–498 (2010).
  MedlineGoogle Scholar
• 18 Kishimoto T. Il-6: from its discovery to clinical applications. Int. Immunol. 22(5), 347–352 (2010).
  Medline CASGoogle Scholar
• 19 Casper C, Chaturvedi S, Munshi N et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-il-6 monoclonal antibody) in multicentric Castleman's. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-15-0134 (2015) (Online).
  MedlineGoogle Scholar
• 20 Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86(2), 592–599 (1990).
  Medline CASGoogle Scholar
• 21 Katsume A, Saito H, Yamada Y et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in il-6 transgenic mice. Cytokine 20(6), 304–311 (2002).
  Medline CASGoogle Scholar
• 22 Screpanti I, Romani L, Musiani P et al. Lymphoproliferative disorder and imbalanced T-helper response in c/EPB beta-deficient mice. EMBO J. 14(9), 1932–1941 (1995).
  Medline CASGoogle Scholar
• 23 Van Gameren MM, Willemse PH, Mulder NH et al. Effects of recombinant human interleukin-6 in cancer patients: a Phase I–II study. Blood 84(5), 1434–1441 (1994).
  Medline CASGoogle Scholar
• 24 Beck JT, Hsu SM, Wijdenes J et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330(9), 602–605 (1994).
  Medline CASGoogle Scholar
• 25 Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8), 2627–2632 (2005). •• Of interest, because this study provided data that supported the first approval anywhere in the world of a treatment for MCD in Japan.
  Medline CASGoogle Scholar
• 26 Actemra (tocilizumab) injection, for intravenous use. 2015 (21 July 2015) (2014).
  Google Scholar
• 27 Community register of medicinal products for human use: sylvant authorisation. 2015 (19 July) (2014).
  Google Scholar
• 28 Sylvant prescribing information. 2015 (19 July) (2014).
  Google Scholar
• 29 Patient medication information: sylvant, siltuximab for injection (2014).
  Google Scholar
• 30 Held S. Janssen's sylvant wins approval in Brazil for rare disease MCD. 2015 (25 July 2015) (2015).
  Google Scholar
• 31 Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J. Clin. Oncol. 3, 1202–1216 (1985).
  Medline CASGoogle Scholar
• 32 Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-cd20 monoclonal antibody. Ann. Hematol. 82(12), 766–768 (2003).
  MedlineGoogle Scholar
• 33 Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur. J. Haematol. 76(2), 119–123 (2006).
  Medline CASGoogle Scholar
• 34 Ocio EM, Sanchez-Guijo FM, Diez-Campelo M et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am. J. Hematol. 78(4), 302–305 (2005).
  MedlineGoogle Scholar
• 35 Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92(3), 670–676 (2001).
  Medline CASGoogle Scholar
• 36 Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann. Intern. Med. 128(8), 657–662 (1998).
  Medline CASGoogle Scholar
• 37 Trikha M, Corringham R, Klein B. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9(13), 4653–4665 (2003).
  Medline CASGoogle Scholar
• 38 Mayer C, Xie L, Bandekar R et al. Dose selection of siltuximab for multicentric Castleman's disease. Cancer Chemother. Pharmacol. 75(5), 1037–1045 (2015).
  Medline CASGoogle Scholar
• 39 Bower M, Stebbing J. Exploiting interleukin 6 in multicentric Castleman's disease. Lancet Oncol. 15(9), 910–912 (2014).
  MedlineGoogle Scholar
• 40 Voorhees PM, Manges RF, Sonneveld P et al. A Phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Hematol. 161(3), 357–366 (2013).
  Medline CASGoogle Scholar
• 41 Orlowski R, Gercheva L, Williams C et al. A Phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-il-6 mab) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 90(1), 42–49 (2015).
  Medline CASGoogle Scholar
• 42 Garcia-Manero G, Gartenberg G, Steensma D et al. A Phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with international prognostic scoring system low- or intermediate-1-risk myelodysplastic syndrome. Am. J. Hematol. 89(9), E156–162 (2014).
  Medline CASGoogle Scholar
• 43 Kurzrock R, Voorhees PM, Casper C et al. A Phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. Clin. Cancer Res. 19(13), 3659–3670 (2013). •• Of considerable interest, because this Phase I study generated positive data for siltuximab in iMCD that led to the Phase II study.
  Medline CASGoogle Scholar
• 44 Angevin E, Tabernero J, Elez E et al. A Phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 20(8), 2192–2204 (2014).
  Medline CASGoogle Scholar
• 45 Davis CC, Shah KS, Lechowicz MJ. Clinical development of siltuximab. Cur. Oncol. Rep. 17(7), 1–9 (2015).
  Medline CASGoogle Scholar
• 46 Castell J, Gomez-Lechon M, David M, Fabra R, Trullenque R, Heinrich P. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12, 1179–1186 (1990).
  Medline CASGoogle Scholar
• 47 Cucuianu A, Paytiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses 66, 352–354 (2006).
  Medline CASGoogle Scholar
• 48 Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 112, 4292–4297 (2008).
  Medline CASGoogle Scholar
• 49 Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116(18), 3627–3634 (2010).
  Medline CASGoogle Scholar
• 50 Maione D, Di Carlo E, Li W et al. Coexpression of IL-6 and soluble IL-6r causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 17(19), 5588–5597 (1998).
  Medline CASGoogle Scholar
• 51 Sylvant (siltuximab) for injection: US prescribing information. Janssen Biotech, Inc., PA, USA (2014).
  Google Scholar
• 52 Xie L, Li LY, Kurzrock R et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin 6 chimeric monoclonal antibody, siltuximab (cnto 328), in patients with b-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. Blood 120, 1365 (2012).
  Google Scholar
• 53 Van Rhee F, Wong RS, Munshi N et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15(9), 966–974 (2014). •• Of considerable interest, because this is the only randomized controlled trial performed for iMCD, which led to approval of siltuximab in the USA, Europe and Canada.
  Medline CASGoogle Scholar
• 54 Cheson B, Pfistner B, Juweid M. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25(5), 57–86 (2007).
  MedlineGoogle Scholar
• 55 Van Rhee F, Casper C, Voorhees P et al. A Phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 6(30), 30408–30419 (2015).
  MedlineGoogle Scholar
• 56 Van Rhee F, Munshi N, Wong R et al. Efficacy of siltuximab in patients with previously treated multicentric Castleman's disease (MCD). J. Clin. Oncol. 32(5s Suppl.), Abstract 8514 (2014).
  Google Scholar
• 57 Sawyer M, Casper C, Munshi N et al. Effect of siltuximab on lean body mass (LBM) in multicentric Castleman's disease (MCD) patients (pts). J. Clin. Oncol. 32(5s Suppl.), Abstract 8576 (2014).
  Google Scholar
• 58 Sylvant (siltuximab): summary of product characteristics. European Medicines Agency, London, UK (2015).
  Google Scholar
• 59 Nishimoto N, Sasai M, Shima Y et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1), 56–61 (2000).
  Medline CASGoogle Scholar
• 60 Van Rhee F, Rothman M, Ho KF et al. Patient-reported outcomes for multicentric Castleman's disease in a randomized, placebo-controlled study of siltuximab. Patient 8(2), 207–216 (2015).
  MedlineGoogle Scholar
• 61 Gherardi RK, Belec L, Fromont G et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mrna in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, m protein, and skin changes (poems) syndrome. Blood 83(9), 2587–2593 (1994).
  Medline CASGoogle Scholar
• 62 El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (anakinra). Mol. Cancer Ther. 9(6), 1485–1488 (2010).
  Medline CASGoogle Scholar
• 63 Mohammed A, Janku F, Qi M, Kurzrock R. Castleman's disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report. J. Med. Case Rep. 9, 45 (2015).
  MedlineGoogle Scholar
• 64 Mori Y, Nishimoto N, Ohno M et al. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J. Med. Virol. 61(3), 332–335 (2000).
  Medline CASGoogle Scholar
• 65 Suthaus J, Stuhlmann-Laeisz C, Tompkins VS et al. Hhv-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 119(22), 5173–5181 (2012).
  Medline CASGoogle Scholar
• 66 Polizzotto MN, Uldrick TS, Wang V et al. Human and viral interleukin-6 and other cytokines in kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 122(26), 4189–4198 (2013).
  Medline CASGoogle Scholar
• 67 Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. Histopathology doi:10.1111/his.12718 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 68 Tocilizumab for KSHV-associated multicentric Castleman disease. 2015 (7/24/2015) (2015).
  Google Scholar
• 69 Turcotte LM, Correll CK, Reed RC, Moertel CL. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr. Blood Cancer 61(4), 737–739 (2014).
  Medline CASGoogle Scholar
• 70 Zhang J, Li C, Lv L et al. Clinical and experimental study of Castleman disease in children. Pediatr. Blood Cancer 62(1), 109–114 (2015).
  MedlineGoogle Scholar
• 71 Ahmed B, Tschen J, Cohen P et al. Cutaneous Castleman's disease responds to anti-interleukin-6 treatment. Mol. Cancer Ther. 6(9), 2386–2390 (2007).
  Medline CASGoogle Scholar
• 72 Munoz J, Naing A, Qi M, Kurzrock R. Cutaneous Castleman disease. Br. J. Haematol. 157(6), 652 (2012).
  MedlineGoogle Scholar
• 73 Van Rhee F, Fayad L, Voorhees P et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J. Clin. Oncol. 28(23), 3701–3708 (2010).
  Medline CASGoogle Scholar